Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

Condition:   Head and Neck Cancer Interventions:   Drug: Nivolumab;   Drug: Cisplatin;   Drug: Docetaxel;   Radiation: Radioimmunotherapy Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials